Reuters logo
CORRECTED-Bayer Q1 core profit beats consensus on strong pharma
April 28, 2014 / 5:45 AM / 4 years ago

CORRECTED-Bayer Q1 core profit beats consensus on strong pharma

(Corrects figure in lead to 11.6 percent from 11 percent)

FRANKFURT, April 28 (Reuters) - German drugmaker Bayer published an 11.6 percent increase in first-quarter underlying operating profit, beating consensus as its pharmaceuticals business posted a strong start to the year.

Bayer said on Monday its quarterly adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.738 billion euros ($3.79 billion).

Sales rose 2.8 percent to 10.555 billion euros and were up 8.4 percent adjusted for currency swings.

Analysts in a Reuters poll had on average seen adjusted EBITDA at 2.593 billion euros and sales at 10.674 billion. Poll:

Bayer confirmed its 2014 outlook for a low to medium single-digit percentage rise in adjusted EBITDA and currency-adjusted sales of around 41-42 billion euros.

$1 = 0.7227 Euros Reporting by Marilyn Gerlach; editing by Keiron Henderson

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below